SynthesisClinical cancer research : an official journal of the American Association for Cancer Research2014

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Osama E Rahma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.